OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
We have demonstrated that histone deacetylase inhibitors (HDACi) can reinstate immune reactivity in colorectal cancer cells by upregulation of elements of the machinery of immune presentation, including MHC class1. We went on to show that the combination of an HDACi with an immune checkpoint inhibitor delivered synergistic anticancer effects in a syngeneic colorectal cancer (CRC) mouse model. We have performed a clinical trial to test this hypothesis in patients with advanced, refractory CRC with positive results. We have adapted our AI/digital pathology programme to develop a biomarker to select CRC patients who are more likely to benefit from this combination immunotherapy and plan to incorporate this into a prospective clinical trial.
